Loading
Monopar Therapeutics

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar is building a drug development pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical experience to help reduce the risk and accelerate the clinical development of its drug product candidates.

Monopar's team is located in San Francisco, CA and Chicago, IL.

Innovative Drugs and Drug Combinations

Licensing, developing and commercializing transformative oncology therapeutics

Why Oncology?

Multiple factors drive our passion for oncology

Corporate Overview

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization. 

Our Research Pipeline

Monopar’s pipeline consists of Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers.



Product Indications Discovery Preclinical Phase 1 Phase 2 Phase 3 Status

MNPR-101-Zr

Imaging Agent for MNPR-101 RIT

Discovery complete

Preclinical complete

Phase 1 in progress

Phase 2 not started

Phase 3 not started

Phase 1 Clinical Trial Active and Recruiting

MNPR-101 RIT

Advanced Solid Cancers

Discovery complete

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Late Preclinical

Early Pipeline

Solid cancers

Discovery complete

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Early Preclinical

Early Pipeline

Solid cancers

Discovery in progress

Preclinical not started

Phase 1 not started

Phase 2 not started

Phase 3 not started

Discovery
Email Alerts

Stay informed and receive company updates straight to your inbox